Search

everythinglearnresearchcommunity

for

Search:↓

Higher levels of retinol-binding protein 4 are found in people with alopecia areata, but these levels don't relate to how severe the condition is.

People with severe hair loss have higher levels of a protein called interleukin 17 in their blood.

Alopecia areata negatively impacts quality of life and work, even with moderate hair loss.

Higher antigliadin antibodies are linked to more severe alopecia areata, suggesting screening for celiac disease in these patients.

Highly active but fewer CD14+CD16- monocytes are found in Alopecia Areata patients, regardless of severity.

Lower Paraoxonase 1 levels in alopecia areata patients suggest antioxidant treatment might help.

Blood tests can help understand the genetic differences in people with alopecia areata, including how severe it is and if it's inherited.

Trichoscopy is better than the hair pull test for tracking alopecia areata.

More effective treatments are needed for severe alopecia areata.

Higher interleukin-15 levels are linked to more severe alopecia areata, but not to age or gender.

Higher MPV and CRP levels may indicate more severe alopecia areata.

The AAPPO questionnaire is a reliable tool for assessing hair loss impact in alopecia areata patients.

The study concluded that yellow dots are a common and useful sign for diagnosing alopecia areata in dark-skinned individuals and may indicate the severity of the condition.

Too much epidermal growth factor can cause hair loss.

Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.

A comprehensive scoring system for alopecia areata severity is needed.

Computer vision techniques can help detect and assess skin conditions like vitiligo, alopecia areata, and dermatitis.

Guidelines help design better trials to compare alopecia areata treatments.

Alopecia areata seriously lowers quality of life, especially affecting self-image, mental health, and social life.

Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.

Alopecia areata and androgenetic alopecia affect quality of life similarly.

Many patients with Alopecia Areata in Korea experience anxiety, depression, and reduced quality of life, which are often unrelated to the severity of hair loss.

Baseline severity and relapse history affect alopecia areata treatment and recurrence.

Baseline severity, disease activity, and relapse history are key to predicting response and recurrence in alopecia areata.

Nemolizumab improved both severe atopic dermatitis and alopecia areata in one patient.

The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.

Kids with vitiligo, psoriasis, or alopecia areata are more likely to experience anxiety, depression, and social challenges.

Platelet-rich plasma may help restore immune balance in bald patches, but its effectiveness in treating hair loss is limited.

A new tool simplifies alopecia areata severity scoring but needs validation.

Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.